NCT04153409View on ClinicalTrials.gov

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

February 15, 2020

Study Completion Date

April 10, 2020

Conditions
Acute Migraine
Interventions
DRUG

LAT8881

Two 30 mg capsules of LAT8881

DRUG

Placebo

Two capsules of placebo

Trial Locations (3)

2148

Paratus Clinical Research, Blacktown, Sydney

2259

Paratus Clinical Research, Central Coast, Kanwal

3124

Emeritus Research, Camberwell

Sponsors
All Listed Sponsors
lead

Lateral Pharma Pty Ltd

INDUSTRY